Roche Walks Away From $6.8B Illumina Takeover Bid
By Moran Zhang | April 19, 2012 2:00 AM EST
Swiss drugmaker Roche Holding AG (ROG.VX) said Wednesday that it decided not to extend beyond Friday a $6.8 billion hostile offer for gene sequencing specialist Illumina Inc. (Nasdaq: ILMN) after determining that the incumbent directors of Illumina will be re-elected.
"We do not believe that a price above Roche's offer for Illumina of $51 per share would be in the interest of Roche's shareholders," Roche Chief Executive Severin Schwan said in a statement.
Roche, the world's biggest maker of cancer drugs, is targeting to expand the market share of its diagnostic products by taking over Illumina. Roche started an offer to acquire the San Diego company's shares for $44.50 each in January. It then raised that to $51 last month.
Roche's offer values the gene-sequencing company at about 88 percent above its closing share price on Dec. 21, when rumors about a potential bid first surfaced. The offer expires Friday at 6 p.m. New York time, Roche said.
Illumina, which has branded itself "the Apple of the genomics business", has rejected Roche's sweetened takeover offer and had repeatedly urged shareholders to vote against Roche's nominees to its board.
Illumina believes the offer is undervaluing its "extraordinary" growth prospects, while Roche has called its bid "full, fair and extremely attractive."
Roche had moved to force Illumina into negotiations by starting a proxy fight to gain control of the San Diego-based company's board, but failed when shareholders backed all four of Illumina's nominees to the board, based on preliminary estimates at the company's annual meeting in New York. Illumina shareholders also rejected Roche's attempt to expand Illumina's board to 11 from nine members.
In view of the "apparent" results, Roche announced it is officially walking away on its own terms.
"Roche will continue to consider options and opportunities to develop further its portfolio of businesses in order to expand its diagnostics leadership position," CEO Severin Schwan said.
Ilumina shares fell as much as 8.3 percent in Wednesday's morning trading, before closing up 1.16 percent, to $44.51 a share, while Roche gained 0.93 percent to $44.47.
To contact the editor, e-mail:
Most Popular Slideshows
- Taylor Swift Named Forbes' Second Highest Paid Country Musician [PHOTOS]
- Forever Lost: Indescribable Anguish for Malaysia Airlines MH17 Families, Remains of Some Victims May Never Be Found (PHOTOS)
- Global Aviation Accidents: UN to Form Safety Task Force, Gov'ts Should Share Intelligence Info to Avert Future Incidents on Flying Over Warzones (PHOTOS)
- Celebrities Suffering From Lupus: Facts About the Disease
Join the Conversation
- Man Swindles Apple for $309,768 in 16 States
- Texas Man Selling Condo With ‘Funniest and Most Revealing Ad’
- Toyota Tops World Sales of Cars, Sells Over 5K Million Vehicles in First Half of 2014
- Air New Zealand Pays $1000 to NZ9 Passengers After Three-Night Delay
- Tweens Fool Their Parents Online, McAfee Reports
- Transfer News: FC Barcelona, Man Utd to Compete for Juan Cuadrado's Signature as Fiorentina Reveal Willingness to Sell
- Hilary Duff's New Music Video Chasing the Sun Goes Viral on YouTube [WATCH VIDEO]
- LeBron James to Return to Miami, Face Heat on Christmas Day 2014
- Shanghai Stock Exchange Will Not Extend Trading Hours
- Qatar's Surging Real Estate Prices Won't Affect Thriving Economy – Report